Clinical Trials · NCT03954834
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 478
- Start date
- Jun 2019
- Locations
- 53 sites, 5 countries
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)